Pfizer Conference Insights: Analyzing Bourla...

By João L. Carapinha

June 11, 2025

Pfizer CEO Albert Bourla’s discussion at the June 2025 Goldman Sachs Healthcare conference centered on Pfizer conference insights regarding the pharmaceutical industry’s evolving policy landscape, strategic priorities, and respons...
Revitalizing Innovation: The Impact of UK Medicine Payment Rates
Blinatumomab Benefit Assessment for ALL and Health Economics
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global He...
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
EU Establishes Expert Panel for Orphan Paediatric Devices
High Orphan Drug Prices Persist Despite Market Exclusivity Expiration
Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Mark...
Hepatitis C Investment Impact: Maximizing Health and Economic Returns in China
First At-Home HPV Testing Approval: FDA Clears Teal Wand
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...